Nitrofurantoin
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() |
||||||||||||||||||||||
General | ||||||||||||||||||||||
Non-proprietary name | Nitrofurantoin | |||||||||||||||||||||
other names |
|
|||||||||||||||||||||
Molecular formula | C 8 H 6 N 4 O 5 | |||||||||||||||||||||
Brief description |
yellow solid |
|||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
ATC code | ||||||||||||||||||||||
Drug class |
Antibiotics , urinary tract anti-infectives |
|||||||||||||||||||||
Mechanism of action |
Bacteriostasis |
|||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 238.16 g mol −1 | |||||||||||||||||||||
Physical state |
firmly |
|||||||||||||||||||||
Melting point |
268 ° C |
|||||||||||||||||||||
pK s value |
7.2 |
|||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
Toxicological data | ||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Nitrofurantoin is an antibiotic drug used to treat urinary tract infections .
Structurally, a synthetic nitrofuran - derivative . It is a chemotherapeutic agent used to treat bacterial diseases of the urinary tract. The drug has a wide spectrum of activity. In the treatment of uncomplicated urinary tract infections in particular, it is the agent of first choice, but it can cause serious side effects if used long-term and in high doses. Nitrofurantoin requires a prescription.
Mechanism of action
Nitrofurantoin induces DNA strand breaks in the prokaryotic cells and thus has a bacteriostatic effect.
application
So far, the active ingredient has mostly been used as a reserve antibiotic for the treatment of urinary tract infections if these cannot be treated with another antibiotic or other antibiotics cannot be used (e.g. in the case of intolerance). In the current S3 guideline for the treatment of uncomplicated urinary tract infections, however, it is recommended as the first choice for the treatment of uncomplicated cystitis due to the favorable resistance situation. The capsules are swallowed whole with sufficient liquid with meals .
Spectrum of activity
Nitrofurantoin only develops its full effect in the urine. It works against:
The following bacteria have a natural resistance to nitrofurantoin, so that this antibiotic is not effective in infections caused by these pathogens:
- Bacteria of the genus Proteus
- Morganella morganii
- Bacteria of the genus Providencia
- Pseudomonas aeruginosa
frequent side effects
- nausea
- Vomit
- Loss of appetite
- fatigue
Occasional side effects
- allergic reactions of the lungs
- Cough, fever, chills
- Chest pain
- Shortness of breath
- Eye tremors
- Drowsiness
- dizziness
- Powerlessness
- a headache
- sleepiness
- Pulmonary fibrosis
Rare side effects
- Inflammation of the liver
- Feeling down (depression)
- Happiness
- confusion
- benign increase in intracranial pressure
- Changes in the blood count (see the package insert)
Side effects in patients with impaired kidney function, anemia or diabetes as well as with vitamin B deficiency:
- Disorder of the nervous system (tingling sensation) in the hands and feet
- Inflammation of the optic nerve
Described side effects
- Itching of the skin
- Hives
- various rashes
- Flaking
- Blistering
- temporary hair loss
Others
Nitrofurantoin has also been causally linked to pleural effusion .
Contraindications
Do not take nitrofurantoin:
- In patients with known hypersensitivity to nitrofurantoin or other nitrofurans
- In patients with renal dysfunction with creatinine clearance below 60 ml / min or with increased creatinine plasma levels.
- With glucose-6-phosphate dehydrogenase deficiency (see «Pregnancy / Breastfeeding» in the package insert).
- For acute porphyria.
- In infants under 3 months of age and at the end of pregnancy (during labor and delivery) because of the theoretical possibility of haemolytic anemia in the fetus or newborns (under 3 months) as a result of the immature erythrocyte enzyme system.
Oliguria, anuria. Polyneuropathy, neuritis. Pulmonary fibrosis.
Special warnings and precautions for use
Because of the alcohol intolerance, alcohol consumption should be completely avoided during therapy with the active ingredient nitrofurantoin. Regular blood counts, liver and kidney values should be checked, especially with long-term therapy. For short-term therapy, a doctor's visit is required after 3 days. Here the urine is checked again.
Children should not take the drug if possible. The drug must not be used in severe renal impairment.
The drug should be discontinued immediately if any of the following symptoms occur:
- Coughing fits
- Shortness of breath
- Chest pain
- fever
- Allergic reaction
- Cholestasis
- Signs of polyneuropathy
synthesis
The synthesis of nitrofurantoin can be done in two steps. First, the hydantoin derivative 3 is synthesized starting from chloroacetic acid and hydrazine :
Here, chloroacetic acid and hydrazine react in a nucleophilic substitution to form aminoglycine ( 1 ). Subsequently, with the addition of potassium cyanate, N- amino- N -carbamoylglycine ( 2 ) is formed, which then forms aminohydantoin ( 3 ) in an intramolecular dehydration .
In the second step, ( 3 ) reacts in a further dehydration with nitrofuran, resulting in the desired nitrofurantoin ( 4 ):
Trade names
Furadantin (D, A, CH), Nifurantin (D), Nifuretten (D), Urodin (CH), Uro-Tablinen (D), Uvamin (CH), as well as generic (D, A)
Nifurantin B6 (D)
literature
- W. Forth, D. Henschler, W. Rummel: General and special pharmacology and toxicology . 9th edition. Urban & Fischer, Munich 2005, ISBN 3-437-42521-8 .
- Recurring bladder infections: When every toilet is on fire. In: Spiegel online. February 25, 2014
Individual evidence
- ↑ a b c d e data sheet nitrofurantoin from Sigma-Aldrich , accessed on May 14, 2017 ( PDF ).
- ↑ Entry on nitrofurantoin. In: Römpp Online . Georg Thieme Verlag, accessed on July 19, 2019.
- ↑ K. Gupta, TM Hooton, PL Roberts, WE Stamm: Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. In: Archives of internal medicine. Volume 167, Number 20, November 2007, pp. 2207-2212, doi : 10.1001 / archinte.167.20.2207 , PMID 17998493 .
- ↑ Thomas Herdegen, Vicki Wätzig: short textbook pharmacology . 3. Edition. Thieme, Stuttgart 2013, ISBN 978-3-13-142293-4 , pp. 592 .
- ↑ Florian ME Wagenlehner, Udo Hoyme, Martin Kaase, Reinhard Fünfstück, Kurt G. Naber, Guido Schmiemann: Clinical guidelines for uncomplicated urinary tract infections (2011) . In: Dtsch Arztebl Int . tape 108 , no. 24 , 2011, p. 415-423 ( aerzteblatt.de [accessed June 20, 2011]).
- ↑ Jürgen Freyschmidt: manual diagnostic radiology. Volume 3, Springer, 2003, ISBN 3-540-41421-5 , p. 591.
- ↑ Berthold Jany, Tobias Welte: Pleural effusion in adults - causes, diagnosis and therapy. In: Deutsches Ärzteblatt. Volume 116, No. 21, (May) 2019, pp. 377-385, here: p. 380.
- ↑ a b Axel Kleemann ; Jürgen Engel; Bernhard Kutscher; Dietmar Reichert: Pharmaceutical Substances - Syntheses, Patents and Applications of the most relevant APIs. , 5th edition, Georg Thieme Verlag KG, 2009, ISBN 978-3-13-558405-8 , p. 981.